EN DE

Lepu Scientech Med Tech (2291) Fair Value & Analysis

Healthcare · HK · Market cap HK$3.7B (≈ $469M) · ISIN CNE1000057M5

What is Lepu Scientech Med Tech really worth?

LS Lepu Scientech Med Tech 2291 · HK
PriceHK$13.29
Fair ValueHK$17.75
Upside+33.6%
Quality68/100

A solid business, trading 25% below our fair value of HK$17.75.

As of Sep 6, 2026, the fair value of Lepu Scientech Med Tech is HK$17.75 per share against a price of HK$13.29, so the fair value sits 34% above the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Lepu Scientech Med Tech for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +28.9 %/yr)
✓Highly profitable · 45.4% net margin
✓generates free cash flow
✓Ranks above peers (10/13)
✓Wide moat 75/100

For context

·3.76% dividend yield
Evidence: High Range HK$12.99 – HK$21.35

Fair value as of: Sep 6, 2026

From 26 valuation models · updated today

Fair value updated Sep 6, 2026, revised from HK$17.69 to HK$17.75 (+0.3%) since Aug 13, 2026. Share price +21.8% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • Solid quality (68/100) at a price below fair value, the discount is the argument here, not the business quality.
  • The price sits in the lower half of our model range, the side with the larger margin of safety.
  • The data supports the verdict: every model runs on fully documented inputs.

Price vs Fair Value (4 years)

HK$31.06 HK$8.67 Fair Value HK$17.75 Nov 2022 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 6, 2026.

How to read this chart

46‑month range HK$8.67 – HK$31.06 · fair‑value band HK$12.99 – HK$21.35 · the HK$13.29 price screens below the HK$17.75 fair value. Dashed = 300-day average. As of Sep 6, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Lepu Scientech Med Tech (2291) currently trades at HK$13.29, while our model-based Fair Value estimate is HK$17.75, implying the stock looks roughly 25.1% undervalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$25.09 per share, and 16 of the 26 models we run sit above the HK$13.29 price. Bear case: the Asset-Based group reads lowest at HK$3.94, and 10 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, Lepu Scientech Med Tech generated revenue of HK$528M at a net margin of 45.4%. Revenue declined 10.9% year over year. It earns a return on equity of 11.9%. The balance sheet holds a net cash position of HK$1.2B. Fundamentals as of Sep 6, 2026

Our scenario range runs from HK$12.99 (bear case) to HK$21.35 (bull case); at HK$13.29, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 60% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at 34%, 2291 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$9.98 HK$13.56 HK$24.73 76
Residual Income HK$5.37 HK$6.10 HK$9.43 75
Growth DCF HK$9.57 HK$14.55 HK$24.28 74
All 26 models by family
DCF Models
FCF DCF HK$9.98 HK$13.56 HK$24.73 76
Owner Earnings HK$11.57 HK$21.59 HK$41.85 70
5Y Revenue Exit HK$7.77 HK$10.69 HK$16.78 69
5Y EBITDA Exit HK$12.07 HK$19.39 HK$33.76 70
5Y P/E Exit HK$13.66 HK$27.58 HK$46.75 65
10Y Revenue Exit HK$8.36 HK$13.61 HK$16.72 65
10Y EBITDA Exit HK$11.57 HK$22.67 HK$42.33 62
10Y P/E Exit HK$12.71 HK$26.02 HK$48.35 58
Earnings-Based
Graham-Dodd HK$4.70 HK$32.81 HK$46.04 63
Lynch FV HK$13.92 HK$19.88 HK$25.85 61
PEG = 1.0 HK$13.92 HK$19.88 HK$25.85 57
EPV HK$9.63 HK$10.62 HK$11.48 70
Dividend Discount
Gordon GGM HK$5.45 HK$10.86 HK$16.44 67
DDM Multi-Stage HK$5.45 HK$9.38 HK$11.46 67
Multiples
P/E Multiple HK$11.41 HK$15.22 HK$19.02 63
P/S Multiple HK$4.00 HK$5.33 HK$6.67 58
P/B Multiple HK$8.82 HK$11.76 HK$14.70 55
EV/EBIT HK$13.51 HK$16.90 HK$20.30 63
EV/EBITDA HK$12.59 HK$15.68 HK$18.76 64
EV/Revenue HK$6.54 HK$7.91 HK$9.28 52
Asset-Based
NCAV (Graham) HK$2.94 HK$3.94 HK$5.88 51
Growth DCF
Growth DCF HK$9.57 HK$14.55 HK$24.28 74
Rev-Margin DCF HK$7.96 HK$11.75 HK$19.19 69
Economic Profit
Residual Income HK$5.37 HK$6.10 HK$9.43 75
ROIC Compounder HK$11.65 HK$15.78 HK$20.05 70
Growth Earnings
Growth-Adj P/E HK$17.57 HK$25.09 HK$32.62 67

Widest divergence: Growth Earnings (HK$25.09) versus Asset-Based (HK$3.94). Highest evidence: FCF DCF (76).

Notify me when 2291 reaches fair value

Put 2291 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 13.3 as of Jul 2, 2026
P/S ratio 6.03 P/E × margin
EPS (TTM) HK$0.0200 price ÷ EPS = P/E 13.3
Dividend yield 3.8%
Net margin 45.4% FY2025
Return on equity 11.9% TTM
More key figures
Profitability
Return on assets (EBIT) 8.3% avg 5y
Operating margin 29.5% TTM
Growth
Revenue (TTM) HK$528M TTM
Revenue growth (YoY) −10.9% 3y avg +28.7%
EPS growth (YoY) −45.6%
Balance sheet & cash flow
Free cash flow HK$145M FY2025
Net cash HK$1.2B FY2025

Figures from reported company fundamentals · as of Sep 6, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 67 · Market factors (momentum, volatility) 38

Profitability 53
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 70
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 60
Disciplined investing over empire-building
Low Volatility 57
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 14
Distance to the 52-week high (market factor)
Net Issuance 72
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the manufacture and sale of interventional treatment series occluders and heart valve medical devices. It operates through Occluder Business and Heart Valve Business segments.

Full company description

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the manufacture and sale of interventional treatment series occluders and heart valve medical devices. It operates through Occluder Business and Heart Valve Business segments. The company also researches, develops, manufacture, and sale interventional treatment series occluders for defective congenital heart disease; and manufacture and sale heart valve medical devices. Its products include atrial septal defect, ventricular septal defect, patent ductus arteriosus, patent foramen ovale, left atrial appendage, and aortic and peripheral occluders, as well as aortic and mitral valve occluder products; atrial septal puncture and procedural accessories; interatrial shunt device; mechanical circulatory support products; and hypertensive device treatment products. In addition, it is involved in manufacturing industry; technology development; and trading activities. The company serves its products through distributors and direct sales. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Lepu Scientech Med Tech reported revenue of 528M CNY in FY2025 versus 223M CNY in FY2021, a compound +24.1%/yr. Reported net income was 240M CNY in FY2025, compounding +42.2%/yr from FY2021.

Growth Quality 95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
HK$528M
Latest YoY
+11.9%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+28.7%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+28.9%
Avg. revenue growth/yr (6Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+28.6%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
+32.9% · in HKD
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+29.1%
Dividend yield3.8%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.51.6% (2020) → 52.4% (2025) · steady
Worst earnings drop124% (2022) (loss year, drop beyond 100%) · in HKD
Revenue +24.1%/yr
FY21 223M CNY
FY22 248M CNY
FY23 326M CNY
FY24 472M CNY
FY25 528M CNY
Net income +42.2%/yr
FY21 58.7M CNY
FY22 −19.8M CNY
FY23 152M CNY
FY24 246M CNY
FY25 240M CNY

Watch 2291: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lepu Scientech Med Tech · Fair Value
HK$17.75 +25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lepu Scientech Med Tech Fair Value". https://www.fairvalue-calculator.com/stock/2291.HK

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside +33% · Top 25%
Return on equity (TTM) 12% · Top 25%
Return on assets 8% · Top 25%
Net margin (TTM) 45% · Top 25%
Operating margin (TTM) 30% · Top 25%
Revenue growth −11% · Bottom 25%
Dividend yield (TTM) 3.8% · Top 25%

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 13.3× · Cheaper than 75% of peers
P/B 1.81× · Pricier than median
P/S (TTM) 6.97× · Pricier than 75% of peers
P/FCF 3.2× · Cheaper than median
EV/EBITDA 8.6× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE78 · sector 0
FUTURE0 · sector 32
PAST48 · sector 5
HEALTH0 · sector 97
DIVIDEND75 · sector 35

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Sep 6, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $112.47 $74.79 −34%
Stryker Corporation SYK $322.12 $186.28 −42%
Medtronic plc MDT $89.97 $65.57 −27%
Boston Scientific Corporation BSX $46.84 $30.73 −34%
Edwards Lifesciences Corporation EW $89.78 $41.02 −54%
Siemens Healthineers AG SHL €39.52 €33.87 −14%
DexCom, Inc DXCM $90.82 $38.95 −57%
GE HealthCare Technologies Inc GEHC $74.82 $64.13 −14%
Koninklijke Philips N.V PHIA €23.69 €14.36 −39%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 −2%

Compare Lepu Scientech Med Tech with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Lepu Scientech Med Tech (2291) overvalued or undervalued?
As of Sep 6, 2026, our model estimates a fair value of HK$17.75 versus a price of HK$13.29, about +34% upside (undervalued).
What is the fair value of 2291?
Our model-based fair value for Lepu Scientech Med Tech is HK$17.75 (as of Sep 6, 2026), built from audited fundamentals. The current price: HK$13.29.
What is the quality score of 2291?
Lepu Scientech Med Tech has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lepu Scientech Med Tech (2291)?
Our model-based price target is the fair value of HK$17.75 (as of Sep 6, 2026) from 26 valuation models. Cautious scenario HK$12.99, optimistic scenario HK$21.35. It is a calculation from audited fundamentals, not an analyst target.
What is the Lepu Scientech Med Tech stock forecast for 2026?
Our models put fair value at HK$17.75, about +34% upside versus a price of HK$13.29 (undervalued). Cautious scenario HK$12.99, optimistic scenario HK$21.35. The calculation is refreshed regularly with new filings.
What is the revenue of Lepu Scientech Med Tech (2291)?
Lepu Scientech Med Tech reported trailing-twelve-month revenue of about HK$528M (latest available figure, as of Sep 6, 2026).
What is the net profit margin of 2291?
The net profit margin of Lepu Scientech Med Tech is about 45.4%, meaning it keeps roughly 45.4% of revenue as net income. Based on the latest reported figures.
Does Lepu Scientech Med Tech pay a dividend?
Lepu Scientech Med Tech currently shows a dividend yield of about 3.76% relative to its recent price (as of Sep 6, 2026).
Free · no account needed

Watch Lepu Scientech Med Tech in the live analysis

One click puts Lepu Scientech Med Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.